In a case of biotech-on-biotech M&A action, Portage Biotech will acquire Tarus Therapeutics and its haul of adenosine receptor antagonists. Westport, Connecticut-based Portage will hand over 2.4 ...
More than two years after acquiring Tarus Therapeutics, Portage Biotech is relaunching Tarus’ adenosine receptor antagonists in a standalone company helmed by a familiar leader. The offshoot, to be ...
Poly adenosine diphosphate-ribose polymerase inhibitors, an important class of anticancer drugs, employ synthetic lethality strategy and are particularly effective against cancers with genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results